Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.943
Peer-review started: April 8, 2021
First decision: May 24, 2021
Revised: May 27, 2021
Accepted: July 9, 2021
Article in press: July 9, 2021
Published online: August 15, 2021
Processing time: 128 Days and 2.5 Hours
Esophageal cancer (ESCA) is a heterogeneous cancer with variable outcomes that are challenging to predict. MicroRNA (miR)-1269a is a newly discovered non-coding RNA that shows promising prognostic prediction in other cancers, but its clinical value in ESCA remains unclear.
This study established a comprehensive staging system that combines clinical characteristics with genetic mutations in ESCA.
This study aimed to determine the prognostic value of miR-1269a, and to develop a nomogram to succinctly predict the prognosis in esophageal carcinoma.
miR-1269a expression in ESCA were detected using quantitative real-time polymerase chain reaction. Then we determined its prognostic value with clinical variables through multivariate Cox analysis. A nomogram based on miR-1269a expression using age and American Joint Committee on Cancer (AJCC) stage was developed and assessed its prognostic performance. Finally, we predicted the target genes of miR-1269a and analyzed their potential function in caner development using Gene Onto
High expression of miR-1269a in ESCA showed poor prognosis in overall survival (OS) and cancer-specific survival (CSS), suffered increased rates of low differentiation and metastasis, and exhibited tumor stage T3 + T4, positive lymph stage, and AJCC stage III + IV. The area under the receiver operating characteristic curve of miR-1269a was 0.716 for OS and 0.764 for CSS. Multivariate Cox analysis revealed that AJCC stage and miR-1269a were independent factors for OS and CSS. Combing with age, we constructed a nomogram for prognostic prediction, which showed excellent perfor
miR-1269a can be used as a potential indicator for the prognosis of esophageal cancer. We developed an easy-to-use nomogram with excellent prognostic prediction for clinical use.
In further research, the molecular mechanism of miR-1304 in esophageal cancer will be elucidated.